Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings ...

新泽西州拉威 - 全球医疗保健领导者默沙东集团（NYSE: MRK）已完成收购Curon Biopharmaceutical的新型双特异性抗体CN201，从而增强其管线中用于治疗B细胞恶性肿瘤和自身免疫性疾病的潜在药物。这笔交易涉及约7.5亿美元的预付款和相关费用，将反映在默沙东集团第三季度的非GAAP业绩中。

2024年9月30日，制药公司默沙东（MRK）成交额为12.43亿美元，在当日美股中排第43名，成交额较昨日减少8.20%，当日成交量为1095.00万。 默沙东（MRK）于2024年9月30日跌0.12%，报113.55美元，该股过去5个交易日跌1.80%，整个9月跌4.14%，年初至今涨4.16%，过去52周涨10.30%。

On Friday, Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $113.69 which represents a slight increase of $0.60 or 0.53% from the prior close of $113.09. The stock opened at $113.17 ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

赛季首冠！袁心玥助瓦基弗女排大逆转基耶里，表现出色斩获7分 ...

直播吧9月29日讯 据昨日合报道，尼克斯接近与森林狼、黄蜂完成三方交易，尼克斯送出兰德尔、迪文岑佐和一个首轮签（2025年前13顺位保护，来自活塞）。尼克斯球员约什-哈特今日更推写道：“昂...我们是认真的吗？”随着随后哈特又更推澄清道：“我在说关于 ...

二个小 默沙东 三个级别的对手联手，居然撼动了世界医药老四的 巨头默沙东的根基，世界药王K药 ...